InsidersTradesSigma
Follow the Neuphoria Therapeutics Inc. share price and the full directors' dealings record of the company, a listed equity based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). The latest transaction was filed on 23 October 2025 (Acquisition). Among the most active insiders: Lynx1 Capital Management LP. All data is accessible without an account.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
1 of 1 declaration
Neuphoria Therapeutics Inc. es una empresa centrada en el desarrollo de tratamientos innovadores para trastornos neurológicos. Cotiza en el mercado XNAS.